ArticleMedical oncology (Northwood, London, England)2019
Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer.
Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Validation of the Tamil Version of the Taste and Smell Questionnaire for Assessing Sensory Dysfunction in Head and Neck Cancer Patients Undergoing Chemoradiotherapy.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Taste Dysfunction in Head and Neck Cancer: Pathophysiology and Clinical Management-A Comprehensive Review.Biomedicines · 2025Review
- Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature.La Radiologia medica · 2024Review
- Article
- Acupuncture Point Selection Patterns for Chemotherapy-Induced Nausea and Vomiting: A Data Mining Analysis.Complementary medicine research · 2024Article
- Impact of radiation dose on patient-reported acute taste alteration in a prospective observational study cohort in head and neck squamous cell cancer (HNSCC).La Radiologia medica · 2023Observational
- Acute Taste Dysfunction in Oropharyngeal Cancer Patients after Transoral Robotic Surgery.The Laryngoscope · 2023Article
- Prospective Evaluation of Taste Function in Patients With Head and Neck Cancer Receiving Intensity-Modulated Radiotherapy.JAMA otolaryngology-- head & neck surgery · 2022Article
- Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Molecular and Neural Mechanism of Dysphagia Due to Cancer.International journal of molecular sciences · 2021Review
- The effect of radiotherapy on taste sensation in head and neck cancer patients - a prospective study.Radiation oncology (London, England) · 2020Article
- Factors Influencing Chemotherapy-Induced Taste Alterations in Cancer Patients Receiving Cisplatin Treatment: A Path Analysis.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysgeusia and nausea are common side effects observed in head and neck cancer patients treated with either exclusive radiotherapy or combined modality treatment. The aim of the present study was to prospectively evaluate dysgeusia, during treatment and follow-up, using the chemotherapy-induced taste alteration scale (CiTAS), a metrics based on 18-items exploring three dimensions (quantitative and qualitative changes in taste perception, and diet-related issues) identified through a four-factor analysis: decline in basic taste, discomfort, phantogeusia-parageusia, and general taste alterations. Moreover, we scored, according to Common Toxicity Criteria Adverse Events, nausea and other treatment-related toxicities. Since, ginger is traditionally used to prevent and/or treat nausea and vomiting, we prophylactically employed a ginger-based supplement named Naumix/Naugin (Gamfarma, Milan, Italy), to potentially mitigate both nausea and taste impairment. Using the CiTAS scale, we highlighted a progressive increase in all dysgeusia dimensions, peaking at the VII week of treatment and a subsequent partial late recovery. In particular, we observed a recovery for discomfort, phantogeusia-parageusia, and general taste alterations at 6 months. Grade 2 nausea, observed to be as low as 12.9% potentially due to the use of ginger, peaked at the III week of treatment. Finally, for patients experiencing nausea, the dysgeusia dimension of discomfort was also relevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.